DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Articles in academic journal >

Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis


File Description SizeFormat
MSM20_1314.pdf176.38 kBAdobe PDFView/Open

Title: Efficacy of Long-Term 4.0 g/Day Mesalazine (Pentasa) for Maintenance Therapy in Ulcerative Colitis
Authors: Takeshima, Fuminao / Matsumura, Masato / Makiyama, Kazuya / Ohba, Kazuo / Yamakawa, Masaki / Nishiyama, Hitoshi / Yamao, Takuji / Akazawa, Yuko / Yamaguchi, Naoyuki / Ohnita, Ken / Ichikawa, Tatsuki / Isomoto, Hajime / Nakao, Kazuhiko
Issue Date: 27-Jul-2014
Publisher: International Scientific Literature Inc.
Citation: Medical Science Monitor, 20, pp.1314-1318; 2014
Abstract: Background: High-dose (4.0 g/day) mesalazine is typically used for induction therapy, but its efficacy as maintenance therapy remains to be determined. We conducted a multicenter retrospective study to investigate the efficacy of continuous treatment with 4.0 g/day of mesalazine. Material/Methods: Japanese ulcerative colitis (UC) patients receiving acute induction therapy with 4.0 g/day mesalazine were enrolled and followed. Those who clinically improved or who achieved clinical remission were categorized into 2 sub-groups according to the median duration of treatment with 4.0 g/day of mesalazine. The clinical relapse frequency and the time to relapse were analyzed. Results: We enrolled 180 patients with active UC, and then 115 patients who clinically improved or who achieved clinical remission after treatment with 4.0 g/day mesalazine were categorized into 2 sub-groups according to the median of treatment duration: a short-term treatment group (≤105 days, n=58) and a long-term treatment group (>105 days, n=57). Overall, 45 (39.1%) patients relapsed: 28 (48.3%) in the short-term treatment group and 17 (29.8%) in the long-term treatment group. This difference was statistically significant (p<0.05). The relapse- free rate in the long-term treatment group was significantly higher than that in the short-term treatment group (p<0.05). The mean time to relapse in the long-term treatment group was significantly longer than that in the short-term treatment group (425.6±243.8 days vs. 277.4±224.5 days; p<0.05). Conclusions: Long-term continuous treatment with high-dose mesalazine (4.0 g/day) may be more effective than short-term treatment for maintenance of remission in UC patients.
Keywords: Colitis, ulcerative - prevention & Control / Colitis, ulcerative - therapy / Mesalamine - administration & Dosage
URI: http://hdl.handle.net/10069/34743
DOI: 10.12659/MSM.890567
Rights: © Med Sci Monit, 2014. / This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
Type: Journal Article
Text Version: publisher
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/34743

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace